| Literature DB >> 35429382 |
Oliver Stirrup1, Maria Krutikov2, Gokhan Tut3, Tom Palmer1, David Bone3, Rachel Bruton3, Chris Fuller2, Borscha Azmi2, Tara Lancaster3, Panagiota Sylla3, Nayandeep Kaur3, Eliska Spalkova3, Christopher Bentley3, Umayr Amin3, Azar Jadir3, Samuel Hulme3, Rebecca Giddings2, Hadjer Nacer-Laidi2, Verity Baynton4, Aidan Irwin-Singer4, Andrew Hayward5,6, Paul Moss3, Andrew Copas1, Laura Shallcross2.
Abstract
General population studies have shown strong humoral response following SARS-CoV-2 vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in Long-Term Care Facility residents and staff following second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.Entities:
Keywords: COVID-19; antibodies; long-term care facilities; vaccination; waning
Year: 2022 PMID： 35429382 PMCID： PMC9047242 DOI： 10.1093/infdis/jiac146
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226